Vera Therapeutics is trading 4.08% down at $30.95 as investors turn cautious and adjust positions ahead of the company's August 6 earnings report.
- The move comes despite a lack of company-specific news today, suggesting the decline reflects risk-off positioning and profit-taking around upcoming results.
- The stock's weakness is notably stock-specific, as broader markets remain firm with both the S&P 500 and Nasdaq trading higher.